Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. Anatomical Site Is Associated with OS in Immunotherapy-Treated R/M HNSCC Patients
3.2. p16+ Is an Independent Prognostic Biomarker in Immunotherapy-Treated R/M OPSCC Patients
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gregoire, V.; Lefebvre, J.L.; Licitra, L.; Felip, E. EHNS-ESMO-ESTRO Guidelines Working Group Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21 (Suppl. 5), v184–v186. [Google Scholar] [CrossRef] [PubMed]
- Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [Google Scholar] [CrossRef] [PubMed]
- Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.M.; Hwu, W.-J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012, 366, 2455–2465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seiwert, T.Y.; Burtness, B.; Mehra, R.; Weiss, J.; Berger, R.; Eder, J.P.; Heath, K.; McClanahan, T.; Lunceford, J.; Gause, C.; et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 2016, 17, 956–965. [Google Scholar] [CrossRef]
- Pilotto, S.; Kinspergher, S.; Peretti, U.; Calio, A.; Carbognin, L.; Ferrara, R.; Bria, E. Immune checkpoint inhibitors for non-small-cell lung cancer: Does that represent a ‘new frontier’? Anticancer Agents Med. Chem. 2015, 15, 307–313. [Google Scholar] [CrossRef] [PubMed]
- Ferris, R.L.; Blumenschein, G., Jr.; Fayette, J.; Guigay, J.; Colevas, A.D.; Licitra, L.; Harrington, K.; Kasper, S.; Vokes, E.E.; Even, C.; et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 2016, 375, 1856–1867. [Google Scholar] [CrossRef] [PubMed]
- Burtness, B.; Harrington, K.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G., Jr.; Psyrri, A.; Basté, N.; Neupane, P.; Bratland, A.; et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019, 394, 1915–1928. [Google Scholar] [CrossRef]
- Gillison, M.L.; Chaturvedi, A.K.; Anderson, W.F.; Fakhry, C. Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma. J. Clin. Oncol. 2015, 33, 3235–3242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pan, C.; Issaeva, N.; Yarbrough, W.G. HPV-driven oropharyngeal cancer: Current knowledge of molecular biology and mechanisms of carcinogenesis. Cancers Head Neck 2018, 3, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ang, K.K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D.I.; Nguyen-Tân, P.F.; Westra, W.H.; Chung, C.H.; Jordan, R.C.; Lu, C.; et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N. Engl. J. Med. 2010, 363, 24–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Argiris, A.; Li, S.; Ghebremichael, M.; Egloff, A.M.; Wang, L.; Forastiere, A.A.; Burtness, B.; Mehra, R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: An analysis of Eastern Cooperative Oncology Group trials. Ann. Oncol. 2014, 25, 1410–1416. [Google Scholar] [CrossRef] [PubMed]
- Vermorken, J.B.; Psyrri, A.; Mesía, R.; Peyrade, F.; Beier, F.; de Blas, B.; Celik, I.; Licitra, L. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: Retrospective analysis of the phase III EXTREME trial. Ann. Oncol. 2014, 25, 801–807. [Google Scholar] [CrossRef] [PubMed]
- Ford, S.E.; Brandwein-Gensler, M.; Carroll, W.R.; Rosenthal, E.L.; Magnuson, J.S. Transoral Robotic versus Open Surgical Approaches to Oropharyngeal Squamous Cell Carcinoma by Human Papillomavirus Status. Otolaryngol. Neck Surg. 2014, 151, 606–611. [Google Scholar] [CrossRef] [PubMed]
- Bauml, J.; Seiwert, T.Y.; Pfister, D.G.; Worden, F.; Liu, S.V.; Gilbert, J.; Saba, N.F.; Weiss, J.; Wirth, L.; Sukari, A.; et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results from a Single-Arm, Phase II Study. J. Clin. Oncol. 2017, 35, 1542–1549. [Google Scholar] [CrossRef] [PubMed]
- Sacco, A.G.; Chen, R.; Worden, F.P.; Wong, D.J.L.; Adkins, D.; Swiecicki, P.; Chai-Ho, W.; Oppelt, P.; Ghosh, D.; Bykowski, J.; et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: An open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021, 22, 883–892. [Google Scholar] [CrossRef]
- Moser, J.C.; Wei, G.; Colonna, S.V.; Grossmann, K.F.; Patel, S.; Hyngstrom, J.R. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol. 2020, 59, 434–437. [Google Scholar] [CrossRef] [PubMed]
- Mok, T.S.K.; Zhang, J.; Lopes, G. Quantifying the benefit of non-small-cell lung cancer immunotherapy–Authors’ reply. Lancet 2019, 394, 1904–1905. [Google Scholar] [CrossRef] [Green Version]
- Carbone, D.P.; Reck, M.; Paz-Ares, L.; Creelan, B.; Horn, L.; Steins, M.; Felip, E.; van den Heuvel, M.M.; Ciuleanu, T.E.; Badin, F.; et al. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 376, 2415–2426. [Google Scholar] [CrossRef] [PubMed]
Age, years (range) | 63.4 (23–86) |
Gender | |
Male | 75% (n = 40) |
Female | 25% (n = 13) |
Smoking history | |
Yes | 83% (n = 44) |
No | 17% (n = 9) |
Anatomical Site | |
Oropharynx | 40% (n = 21) |
Oral Cavity | 28% (n = 15) |
Larynx | 19% (n = 10) |
Other | 13% (n = 7) |
Definitive treatment | |
Non-Surgical | 55% (n = 29) |
Surgical | 45% (n = 24) |
Time to recurrence (months after definitive treatment) | 7 (1–57) |
Recurrence | |
Local/Regional | 21% (n = 11) |
Distant | 79% (n = 42) |
Immunotherapy | |
Pembrolizumab | 28% (n = 15) |
Nivolumab | 70% (n = 37) |
Both | 2% (n = 1) |
Clinicopathologic Characteristics | p16+ (n = 16) | p16- (n = 5) | p Value |
---|---|---|---|
Age | 65 | 58 | 0.23 |
Gender Male Female | |||
94% (n = 15) 6% (n = 1) | 40% (n = 2) 60% (n = 3) | 0.03 | |
Smoking History Yes No | 75% (n = 12) 25% (n = 4) | 80% (n = 4) 20% (n = 1) | 1 |
Anatomical Site Tonsil/Oropharynx Base of Tongue | 69% (n = 11) | 60% (n = 3) | 1 |
31% (n = 5) | 40% (n = 2) | ||
Definitive treatment Non-surgical Surgical | 88% (n = 14) | 40% (n = 2) | 0.06 |
12% (n = 2) | 60% (n = 3) | ||
Time to recurrence (months after definitive treatment) | 17 (1–57) | 7 (1–26) | 0.21 |
Recurrence Local/Regional Distant | 12% (n = 2) 88% (n = 14) | 60% (n = 3) 40% (n = 2) | 0.23 |
Immunotherapy Pembrolizumab Nivolumab Both | 25% (n = 4) 69% (n = 11) 6% (n = 1) | 60% (n = 3) 40% (n = 2) | 0.29 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Clancy, K.; Hamill, C.S.; O’Neill, W.Q.; Vu, B.; Thuener, J.; Gui, S.; Li, S.; Fowler, N.; Rezaee, R.; Lavertu, P.; et al. Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Cancers 2021, 13, 4861. https://doi.org/10.3390/cancers13194861
Clancy K, Hamill CS, O’Neill WQ, Vu B, Thuener J, Gui S, Li S, Fowler N, Rezaee R, Lavertu P, et al. Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Cancers. 2021; 13(19):4861. https://doi.org/10.3390/cancers13194861
Chicago/Turabian StyleClancy, Kate, Chelsea S. Hamill, W. Quinn O’Neill, Brandon Vu, Jason Thuener, Shanying Gui, Shawn Li, Nicole Fowler, Rod Rezaee, Pierre Lavertu, and et al. 2021. "Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients" Cancers 13, no. 19: 4861. https://doi.org/10.3390/cancers13194861